Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
Sudan war ‘being fought on women’s bodies’: Survivors detail sexual assault - 2Exploring the Difficulties of Beginning a Family: Individual Experiences
- 3Instructions to Expand Your Advantages from an Open Record Reward
- 4Popular Film Areas: A Worldwide Manual for Film Enchantment
- 5The cheap health insurance promoted by Trump officials has this catch
- Satellite space quiz: What's orbiting Earth?
- Scientists uncover an ant assassination scheme that helps a parasitic queen rise to power
- Figure out How to Adjust Your Handshake to Various Societies
- Enormous Credit And All that You Really want To Be aware
- Apollo vs. Artemis: What to know about NASA's return to the moon
- Dark matter obeys gravity after all — could that rule out a 5th fundamental force in the universe?
- Wisconsin archaeologists identify 16 ancient canoes in a prehistoric lake 'parking lot'
- Scientists document a death from a meat allergy tied to certain ticks
- Mountain Trekking on a Tight spending plan: Tracking down the Right Bicycle
